Compare · BSX vs CLPT
BSX vs CLPT
Side-by-side comparison of Boston Scientific Corporation (BSX) and ClearPoint Neuro Inc. (CLPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CLPT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 217.5x CLPT ($294.1M).
- Over the past year, BSX is down 55.9% and CLPT is down 66.8% - BSX leads by 11.0 points.
- BSX has been more active in the news (4 items in the past 4 weeks vs 3 for CLPT).
- BSX has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- Boston Scientific Corporation
- ClearPoint Neuro Inc.
- Price
- $44.38+0.50%
- $9.07-5.67%
- Market cap
- $63.97B
- $294.1M
- 1M return
- +1.88%
- -34.05%
- 1Y return
- -55.85%
- -66.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 5
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest CLPT
- ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
- Director Richards Timothy T. was granted 319 shares, increasing direct ownership by 0.36% to 87,863 units (SEC Form 4)
- Director Fletcher R John was granted 993 shares, increasing direct ownership by 0.76% to 132,004 units (SEC Form 4)
- CEO and President Burnett Joseph exercised 12,517 shares at a strike of $3.47, increasing direct ownership by 11% to 130,720 units (SEC Form 4)
- SEC Form 10-Q filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ClearPoint Neuro Reports Second Quarter 2026 Results
- ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
- ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
- Director Richards Timothy T. was granted 222 shares, increasing direct ownership by 0.25% to 87,544 units (SEC Form 4)